Collectively, our data indicate not only that ERBB2R678Q is one of the most frequent ERBB2 mutations in cancer globally, but also indicate for the first time that ERBB2R678Q is particularly enriched in endometrial cancer. This evidence concerns the gene ERBB2 and cancer.